Caudal Dexmedetomidine
DrugDrug:Caudal bupivacaine 0.25% 1ml/kg
Drug: Caudal dexmedetomidine 1µg/kg
Intravenous: 10 ml normal saline
sevoflurane Induction and maintenance of anesthesia
Other names: dexmedetomidine, Precedex
NCT Number: NCT02416063
The aim of this prospective randomized double-blind study was to compare the analgesic efficacy and the side effects of dexmedetomidine (1 µg.kg-1) co-administered with bupivacaine for caudal analgesia or intravenously in children undergoing infra-umbilical surgery.
Looking for future studies?
Notify Me1 year–6 year
All sexes
Interventional
Phase 2
Dexmedetomidine is used increasingly in pediatric anesthesia practice to prolong the duration of action of caudal block with a local anesthetic agent.But which route of administration of dexmedetomidine is the most beneficial remains unknown.
The investigators performed prospective randomized double-blind study to compare the effects of caudal dexmedetomidine with intravenous dexmedetomidine on postoperative analgesia after caudal bupivacaine in children undergoing infra-umbilical surgery.
75 children (ASAⅠorⅡ,aged 1-6 yr) undergoing infra-umbilical surgery were included in this study. Anesthesia was induced with sevoflurane via a facemask, followed by placement of a laryngeal mask airway. Anesthesia was maintained with sevoflurane 2-3% in oxygen-air.Then,caudal block was applied. Patients were randomly assigned in three groups. Group B-Dcau (n = 25): Caudal bupivacaine 0.25% 1ml/kg plus dexmedetomidine 1µg/kg and 10 ml normal saline i.v.;Group B-Div (n = 25): bupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg(10 ml)i.v.;Group B(n = 25): bupivacaine 0.25% and 10 ml normal saline intravenous
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Drug:Caudal bupivacaine 0.25% 1ml/kg
Drug: Caudal dexmedetomidine 1µg/kg
Intravenous: 10 ml normal saline
sevoflurane Induction and maintenance of anesthesia
Other names: dexmedetomidine, Precedex
Drug:Caudal bupivacaine 0.25% 1ml/kg.
Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml
sevoflurane Induction and maintenance of anesthesia
Other names: precedex
Drug:Caudal bupivacaine 0.25% 1ml/kg
Intravenous: Normal saline 10 ml
sevoflurane Induction and maintenance of anesthesia
Other names: normal saline
Time frame: 24 hours
Time to first rescue medication. The time from end of surgery to the first requirement of postoperative analgesia,pain score ≥4
Time frame: 2 hours
behaviour score was recorded throughout the post-anesthesia care unit stay at 15-minute time intervals.
Time frame: 1 hour
Sevoflurane concentration required to maintain Bispectral Index (BIS) monitor reading between 40 and 60
Time frame: 2 hours
Perioperative blood pressure readings
Time frame: 2 hours
Perioperative heart rate readings
Time frame: 2 hours
Participants will be followed for the duration of PACU stay, an expected average of 2 hours
Time frame: 24 hours
postoperative pain score will be assessed over 24 hours
Time frame: 24 hours
side effects including nausea, vomiting and urinary retention and lower limb weakness
University of Jordan
Other
Caudal Versus Intravenous Dexmedetomidine for Caudal Analgesia in Children: A Randomised Controlled Double Blind Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07342751
Children, Only, Neurologic Manifestations
Tarsus, Turkey (Türkiye)
View Trial DetailsNCT07025161
Neurologic Manifestations, Pain
Orlando, Florida, United States
View Trial DetailsNCT05283980
Acute Pain, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT06869369
Behavior, Motor Activity
Kütahya, Turkey (Türkiye)
View Trial Details